Table 2. Treatment details of the different groups.
| Treatment | NACT+CCRT (n=73) | CCRT (n=73) | χ2 | p-value | |
|---|---|---|---|---|---|
| No. of patients | No. of patients | ||||
| Neoadjuvant chemotherapy | |||||
| TP (No. of cycles) | 2 | NA | |||
| NACT dose reduction | |||||
| Yes | 1 (1.4) | NA | |||
| No | 72 (98.6) | NA | |||
| CCRT cycles | 0.245 | 0.621 | |||
| 1 | 5 (6.8) | 7 (9.6) | |||
| 2 | 68 (93.2) | 66 (90.4) | |||
| Completion of radiation therapy | 12.332 | 0.001 | |||
| Yes | 73 (100) | 68 (93.2) | |||
| No | 0 (0) | 5 (6.8) | |||
| Days of radiotherapy | 58 (48–61) | 57 (48–67) | 1.486 | 0.225 | |
Values are presented as median (range) or number (%).
CCRT, concurrent chemoradiotherapy; NA, not applicable; NACT, neoadjuvant chemotherapy; TP, paclitaxel combined with cisplatin.